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Key Points
• 18FDG PET/CT is a very
important staging tool for
patients with PMBCL.
• Metabolic activity defined by
TLG on the baseline PET
scan is a powerful predictor
of PMBCL outcome.
The International Extranodal Lymphoma Study Group (IELSG) 26 study was designed
to evaluate the role of 18F-fluorodeoxyglucose (18FDG) positron emission tomography/
computed tomography (PET/CT) in the management of primary mediastinal (thymic)
large B-cell lymphoma (PMBCL). We examined the prognostic impact of functional PET
parameters at diagnosis. Metabolic activity definedby themaximumstandardized uptake
value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) was
measured on baseline 18FDG PET/CT following a standard protocol in a prospectively
enrolled cohort of 103 PMBCL patients. All received combination chemoimmunotherapy
withdoxorubicin-andrituximab-basedregimens;93hadconsolidationradiotherapy.Cut-
off valuesweredeterminedusing the receiver-operating characteristic curve. At amedian
follow-up of 36 months, progression-free survival (PFS) and overall survival (OS) were 87% and 94%, respectively. In univariate
analysis, elevated MTV and TLG were significantly associated with worse PFS and OS. Only TLG retained statistical significance for
bothOS (P5 .001) andPFS (P < .001) inmultivariate analysis. At 5 years, OSwas 100% for patientswith lowTLGvs 80% for thosewith
highTLG (P5 .0001),whereasPFSwas99%vs64%, respectively (P< .0001). TLGonbaselinePETappeared tobe apowerful predictor
of PMBCL outcomes and warrants further validation as a biomarker. The IELSG 26 study was registered at www.clinicaltrials.gov as
#NCT00944567. (Blood. 2015;126(8):950-956)
Introduction
Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a dis-
tinct clinicopathological1-3 andmolecular4,5 subtypeofdiffuse largeB-cell
lymphoma (DLBCL) arising froma small population ofB cellswithin the
thymus. It is characterized by a rapidly progressive anterior mediastinal
mass, often with local invasion and compressive syndromes, and by re-
currence at unusual extranodal sites.6 PMBCL commonly affects young
adults, and treatment with aggressive chemotherapy regimens and
rituximabwith or without radiotherapy appears to yield better outcomes
than inotherDLBCLs,partlyas a result of theyoungerageandearlier stage
at presentation, with 5-year survival rates of over 90% in recent studies.7,8
However, salvage treatment of the fewpatients failedby initial therapy
has a poor outcome, as a result of rapidly emerging chemorefractory
disease, often around the completion of thefirst course of treatment.9,10 If
it were possible to predict this important minority, it would allow for the
development of risk-stratified approaches such as early intensification
with infusional regimens or even elective myeloablative therapy.
Hence, there is a need for reliable prognostic markers. The Inter-
national Prognostic Index (IPI), the conventional tool used to predict
outcome for DLBCL, has limited utility in PMBCL because of the
young patient age and the usual confinement of the disease to the
mediastinum.11 This is reflected in the observation that most patients
have low-risk IPI scores at presentation.8,12
18F-fluorodeoxyglucose (18FDG) positron emission tomography/
computed tomography (PET/CT) is increasingly used to monitor
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treatment response and guide clinical decisions on treatment strategies
for FDG-avid lymphomas, including PMBCL.13-15 We have previously
shown8 that liver FDG uptake was the optimal cutoff value to predict
outcome,providingavalidationof theutility for a5-point scale (Deauville
criteria, initially developed for the interim PET evaluation of Hodgkin
disease and DLBCL)16 in end-of-therapy PET evaluation of PMBCL.
The objective of the present study was to investigate whether the
main quantitative baseline PET-derived metabolic parameters can pre-
dict prognosis, and to compare these parameters with the commonly
used clinical indices, in patients with PMBCL.
Patients and methods
Patient population
Between January 2007 and July 2010, 125 patients with histologically proven
PMBCL were prospectively enrolled in the International Extranodal Lym-
phoma Study Group (IELSG) 26 study (http://clinicaltrials.gov/ct2/show/
NCT00944567) and treated with the R-CHOP (rituximab plus cyclophospha-
mide, doxorubicin, vincristine, and prednisone) or R-CHOP-like R-VACOP-B
(rituximab plus etoposide, leucovorin, doxorubicin, cyclophosphamide, vincris-
tine, prednisone, and bleomycin) or R-MACOP-B (rituximab plusmethotrexate,
leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and
bleomycin) regimens according to local policy. Consolidation with mediastinal
involved field radiotherapy as indicated by local guidelines was allowed; all
patients treated received, within 8weeks of the last dose of chemotherapy, a dose
of at least 30 Gy on the original tumor volume. Treatment details have been re-
ported previously.8 The study was conducted in accordance with the precepts
of the Helsinki declaration and received approval from the local research ethical
committee of each participating center.
18FDG-PET imaging procedures
The study protocol included mandatory technical procedures for the acquisition
and elaboration of PET imaging, based on the state of the art at the timewhen the
study was planned.17 Baseline PET scans were performedwithin 14 days before
thefirst chemotherapy. In caseswhere urgent treatmentwas required and thePET
scan couldnot be performedbefore therapy started, the baseline scanwasomitted
after discussion with the clinical coordinators; these cases were excluded from
this analysis. PET/CT imaging was performed on full-ring integrated PET/CT
systems.Each centerwas required to followanactive quality-control andquality-
assessment protocol.17 PET and CT images were acquired in the same session.
CT scans obtainedwith a low-dose protocol were used for attenuation-correction
of the PET images. All patients were fasting for at least 6 hours before the
injection of 250 to 370 MBq (4.5 MBq/kg) 18FDG. Blood glucose measured
before injectionof the radiotracerwas,160mg/dL in all patients. PETdatawere
acquired in 2- or 3-dimensional mode from the midthigh toward the base of the
skull after a standardized uptake time of 60 minutes (65 minutes). The PET
acquisition time was at least 3 minutes per bed position. Images were re-
constructed with validated and commercially available iterative algorithms, and
standardized uptake values (SUV) were automatically calculated. All PET/CT
image data were stored in Digital Imaging and Communications in Medicine
format and sent to the core laboratory for central review. The adherence to the
technical protocol requirements was centrally controlled for each data set.
A central blind analysis was performed by one trained nuclear physician
(L.C.) without information on the clinical outcome.
18FDG PET parameters
The 18FDG-PET/CT images were obtained at baseline for initial staging in 103
out of 125 patients and analyzed following a standard protocol on a dedicated
workstation (Siemens SyngoMMWPWorkstation VE36A; Siemens, Erlangen,
Germany). Dedicated software (Syngo TrueD) automatically estimated the
average and maximum SUV (SUVmean and SUVmax) and metabolic tumor
volume (MTV) of the entire mediastinal lesion using an isocontour threshold
method based on 25% of the SUVmax. In 8 cases, the boundaries of the lesion
estimated automatically were partly manually redrawn to exclude physiological
cardiac activity . The total lesion glycolysis (TLG) was then calculated as the
product of SUVmean and MTV.18
After an experimental evaluation of different threshold levels (20%, 25%,
30%,35%,41%, and50%of theSUVmax) carriedout on a subgroupof 20cases,
25% of the SUVmax was identified as the best cutoff value. The choice of the
threshold was based on visual comparative analysis performed by 2 independent
observers (L.C. and L.G.), taking into account the best fit between “metabolic
edges” and anatomical boundaries, in particular at the interface between tumor
lesion and lung tissue, which is the most clearly identifiable on the CT low-dose
images. The presence of extramediastinal disease (found in 14/103 baseline PET
scans) contributed significantly to the MTV in only 1 patient (29% of the total
volume), whereas in all the others, the lesions were very small (usually single
FDG-positive distant lymph nodes), involving ,5% of the MTV value. This
methodology showed very high interobserver reproducibility (Pearson correla-
tion coefficient .0.99 and P , .0001) for the calculation of all quantitative
parameters.
Statistical methods
ThePET-associated functional parameterswere analyzed as both continuous and
dichotomized variables, using receiver-operating characteristic (ROC) analysis
to identify the optimal cutoff point. Overall survival (OS) and progression-free
survival (PFS) were defined according to the revised National Cancer Institute
criteria13 and estimated using the Kaplan-Meier or life-table method as appro-
priate. Follow-up was calculated as themedian time to censoring using a reverse
Kaplan-Meier analysis.19 Differences between survival curves associated with
discrete or dichotomized variables were analyzed using the log-rank test. Cox
regression was used to estimate the hazard ratio (HR) and its confidence interval
(CI). The exact 95% CIs were calculated for incidence percentages. P values of
# .05 (2-sided test) were considered to indicate statistical significance. Statistical
analysis was conducted using the STATA 11 software package (Stata Corp,
College Station, TX).
Table 1. Patient clinical characteristics at presentation
Characteristic (n 5 103 unless
otherwise specified) No. (%) of patients
Age
Median (interquartile range), y 33 (26-41)
#60 y 97 (94)
Female sex 63 (61)
Performance status
ECOG 0-1 88 (85)
ECOG .1 15 (15)
B-symptoms at presentation 38 (37)
Bulky disease
Max mediastinal lesion .7 cm 89 (86)
Max mediastinal lesion .10 cm 54 (52)
Extramediastinal involvement $1 site 14 (14)
Bone marrow involvement 2 (2)
Ann Arbor stage
I-II 97 (94)
III-IV 6 (6)
LDH .normal upper value* 77 (75)
IPI
Low and low-intermediate risk 99 (96)
Intermediate-high and high risk 4 (4)
aaIPI (n 5 97)
Low and low-intermediate risk 82 (85)
Intermediate-high and high risk 15 (15)
Front-line treatment
R-CHOP or R-CHOP like regimen* 16 (16)
R-VACOP-B or R-MACOP-B regimen* 87 (84)
RT 93 (90)
RT, consolidation mediastinal radiotherapy.
*Details on the immunochemotherapy regimens and radiotherapy plans have
been previously reported.8
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Results
Detailed clinical features and outcome of the patients enrolled in the
IELSG 26 study have been published previously.8 Baseline PET/CT
studieswere available in103out of 125patients, havingbeenomitted in
20 patients because of the urgency of treatment and excluded in 2 cases
(after central control) on technical grounds due to unacceptable length-
ening of the uptake time. Table 1 summarizes the demographic and
clinical characteristics of the 103 patients included in the present
analysis. All had initial treatment with rituximab- and anthracycline-
containing regimens, and 93 also had consolidation radiotherapy to the
mediastinum. At amedian follow-up of 36months (interquartile range,
31-45 months), 13 patients had disease progression or relapse and 6
had died. The estimated 5-year PFS and OS rates were 87% (95% CI,
79%-92%) and 94% (95% CI, 87%-97%), respectively.
The description of the baseline functional PET parameters studied,
SUVmax, MTV, and TLG is depicted in Table 2, which summarizes
the results of the ROC analysis used to identify optimal cutoff points.
In univariate analysis of thePETparameters as continuous variables
(Cox regression), a significantly higher risk of progression was asso-
ciated with an increase in MTV (HR, 1.36; 95% CI, 1.16-1.61 for any
increment of 102mL,P, .001) andTLG(HR,1.40; 95%CI, 1.25-1.58
for any increment of 103 mL; P , .001), but not with an increase in
SUVmax (HR, 1.08; 95% CI, 0.98-1.18 for any increment of 1 unit;
P 5 .119). OS also appeared to be significantly correlated with an
increase in either MTV (HR, 1.39 for each increment of 102 mL;
95% CI, 1.08-1.77; P 5 .009) or TLG (HR, 1.47 for each 103-unit
increment; 95%CI, 1.22-1.76; P, .001), but not SUVmax (HR, 1.11;
95% CI, 0.97-1.27 for any increment of 1 unit, P5 .117).
Univariate analysis of dichotomized parameters (log-rank test)
showed a statistically significant association of high SUVmax, MTV,
and TLG with worse PFS and OS (Figure 1). Elevated TLG andMTV
weremore frequently seen in patientswith bulk.10 cm (supplemental
Table 1, available on the BloodWeb site). Among the clinical features
at presentation, bulk.10 cmwas also associated with shorter PFS, but
not OS (Table 3), whereas no impact on outcomewas seen in this study
population for gender, age, performance status, B-symptoms, serum
lactate dehydrogenase (LDH), stage, IPI, and age-adjusted IPI (aaIPI)
(supplemental Table 2). Nevertheless, on multivariate analysis
(Table 4), only TLG retained statistical significance for both OS and
PFS controlling forMTV (Coxmodels for either PFS orOS) and tumor
bulk (included only in the Cox model for PFS).
Long-term outcome was significantly better for patients with low
TLG (below the cutoff value) compared with those with high TLG
(above the cutoff value), with 5-year OS of 100% vs 80% and 5-year
PFS of 99% vs 64%, respectively (Figure 1).
Despite limited statistical power, baseline TLG remained the
strongest predictor of outcome for the 82 patients with stage I or II
disease in univariate analysis of OS (log-rank test, P5 .0027) and PFS
(log-rank test, P 5 .0001), as well as in Cox models controlling for
MTV(HR,4.21withP5 .018 forOS;HR,1.70withP5 .009 forPFS).
Discussion
There is increasing evidence of the prognostic value of quantita-
tive parameters obtained from initial staging by 18FDG-PET/CT in
patients with high-grade non-Hodgkin lymphoma, in addition to the
standard qualitative visual analysis.15,20,21 Initially, SUVwas themost
widely studied parameter.22-24 More recently, growing recognition ofTa
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volume-based metabolic assessment has emerged, including MTV and
TLG as promising prognostic indices in solid tumors,25 multiple mye-
loma,26 and malignant lymphomas.27-30 Among these functional param-
eters, TLG appears of particular interest as a prognostic pointer in
DLBCL.27,31-35However, no specific study has so far addressedPMBCL
as a distinct subtype2-6 inwhich themetabolic response rate appears clearly
inferior to that seen in other DLBCLs and Hodgkin lymphoma.7,8,36
Although the overall results of treatment of PMBCLare favorable,7,8
there remains a clear minority in whom the initial treatment fails,
following which second-line treatment is frequently unsuccessful.9,10
In a retrospective series from the Princess Margaret Hospital in
Toronto, the overall response rate to salvage chemotherapy (25% vs
48%) and 2-year OS after progression or relapse (15% vs 34%) were
significantly inferior in 37 patients with relapsing or refractory PMLCL
compared with a control group of 143 relapsing patients with other
DLBCLs.9 In a retrospective Italian series, 138 consecutive patients
were treated with the same chemotherapy combinations used in this
study (CHOP or MACOP-B/VACOP-B) but without rituximab.
Figure 1. Estimates of OS and PFS according to the value of functional 18FDG-PET parameters in the PET/CT scan performed during the initial staging of 103
patients with primary mediastinal large cell lymphoma enrolled in the IELSG 26 prospective study. (A-C) Kaplan-Meier estimates of OS. (D-F) Kaplan-Meier estimates
of PFS. Cutoff values are reported in Table 2. High, above the cutoff values calculated by ROC analysis; low, at or below the cutoff values calculated by ROC analysis.
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Seventy-five percent of patients in complete remission received
consolidation radiotherapy. Event-free survival and OS for patients
treatedwithMACOP-B/VACOP-Bwere significantly better, but all the
patients with stable disease or progression during chemotherapy (26)
and all those relapsing after initial remission (12) died of lymphoma,
irrespective of first-line and subsequent treatment type.10 In contrast to
this finding, other studies have reported good outcomes in small groups
of patients with chemosensitive relapse treated with high-dose therapy
andautologousstemcell rescue.9,37Theyshowed that chemotherapyre-
sponsiveness immediately before transplantation is the strongest sur-
vival predictor. All these results highlight the need for studies focused
on identifying poor-risk PMBCL patients to test novel induction and
salvage strategies in advance of overt treatment failure.
Most patients with PMBCL present before the age of 60 years with
early symptoms due to bulky mediastinal lesions that infiltrate the
adjacent thoracic structures. For this reason, they rarely have other ad-
verse prognostic factors.6 The IPIwas originally developed forDLBCL,
and studies of its utility inPMBCLhavebeen contradictory.10,38-40This
may in part reflect differences in assigning stage when contiguous
extranodal sites are involved.41 Moreover, the fact that most patients
have elevated LDH reduces the usefulness of its discriminatory power
and further affects the utility of IPI and aaIPI.38
As confirmed in the current series, conventional clinical prognostic
indices for DLBCL, such as IPI and aaIPI, have only limited utility of
identifying thosewhomaybenefit fromdifferent treatment strategies.8,12
We showed that TLG, which represents a combined assessment of
tumor volume and metabolism on baseline 18FDG-PET/CT, was the
most robust predictor of outcome not only as a dichotomized variable
but also as a continuous parameter, irrespective of the cutoff point. The
negative predictive power is extremely high, as there were no deaths
and only 1 relapse among the patients with low TLG at diagnosis.
Our study was conducted in a large number of uniformly treated
PMBCL patients. A small pilot study of 20 patients with DLBCL from
the Massachusetts General Hospital also suggested that high baseline
TLG may identify patients who are at increased risk of relapse after
conventional R-CHOP34. A survey from South Korea of 140 patients
with DLBCL treated with R-CHOP showed that TLG is a better
predictor of outcome than the IPI.27 Our study represents the largest
prospectively collected series of PMBCL investigated with a central
review of PET scans in which the quantitative functional parameters
were retrospectively analyzed. The PET imaging was obtained follow-
ing a strictly defined technical procedure, although detailed cross-
calibration for equipment at the different centers was not possible. This
may represent a limitation for a study focused on quantitative variables;
however, our results are in keepingwith thefindings of the other studies
from the United States and Korea and seem particularly promising for
the early prediction of treatment failure in PMBCL.
The use of TLG in routine clinical practice would be premature, as
there is a lack of a standardizedmethodology for the estimation ofMTV
and the TLG derived from this. Different methods and a wide range of
threshold levels have beenproposed to calculate the volume-basedPET
parameters either in solid tumors or in different subtypes of lymphoma
(mainlyDLBCL).25-35,42-45Moreover, there are no published technical
references about the methodology for the calculation of the volume-
based PET parameters and definition of specific cutoff values in
PMBCL.
Taking into account these points and the features of this disease,
which is characterized by its thymic origin and presentation with a
bulky FDG-avidmediastinal mass, we elected to experimentally define
the PMBCL-specific volumetric PET parameters.
We estimated theMTV of PMBCL using an isocontour threshold
method based on 25% of the SUVmax, which is lower than the 41%
proposed byBoellard et al46 for the evaluation of tumoral lesions and
tested by Meignan et al in Hodgkin lymphoma and DLBCL.44
However, our choice of a 25% threshold is justified by the very high
FDG uptake currently found in the large and usually single PMBCL
presenting mass (in our population, the median SUVmax was 18.8,
with an interquartile range of 15.5 to 23) and is in keeping with other
reports demonstrating that the ideal threshold (ie, the one that most
accurately reflects the pathological tumor size) is inversely propor-
tional to the lesion SUVmax.43,45 In this relationship, the best thresh-
old is between 30% and 20%when SUVmax is between 20 and 30,45
and our results are in line with these findings.
We are aware that the use of a relatively low cutoff valuemay result
inMTVoverestimation in patients with small masses and reducedmet-
abolic activity; however, this risk does not apply to this study popu-
lation,where.85%of patients had amaximum tumor diameter.7 cm
andonly4patientshadaSUVmax,11.Moreover, tomitigatepotential
bias, TLG was homogenously estimated in all patients during the
central review of PET scans.
Hence, the effectiveness of TLG to risk stratify patients and the
possibility of further improving the positive predictive value by
combining TLG with other clinical and imaging parameters may
warrant further studies. Indeed, this easily and early accessible
parameter can help identify the few PMBCL patients who will
eventually relapse and may be useful for designing trials aimed at
Table 3. Univariate analysis (life tables and log-rank test) of the
difference between OS and PFS according to dichotomized
baseline PET parameters and the presence of a bulky lesion
Parameter 5-y OS (95% CI) P 5-y PFS (95% CI) P
SUVmax .0025 .0065
Low 99% (91%-99.8%) 93% (84%-97%)
High 83% (64%-93%) 73% (54%-86%)
MTV .0036 ,.0001
Low 100% (n.a.%) 95% (88%-98%)
High 86% (72%-94%) 55% (31%-73%)
TLG .0001 ,.0001
Low 100% (n.a.%) 99% (90%-99.8%)
High 80% (62%-91%) 64% (45%-77%)
Bulky disease .120 .013
,10 cm 98% (86%-99%) 96% (85%-99%)
$10 cm 91% (79%-96%) 80% (66%-88%)
The presence of a bulky lesion was statistically significant only for PFS. All the
remaining baseline clinical parameters, namely, gender, age, performance status,
B-symptoms, LDH, stage, and the international prognostic indices, had no statistically
significant impact on both OS and PFS and are not included in this table but are
reported in the online appendices. Cutoff values used for the dichotomization of
functional PET parameters (SUVmax, MTV, TLG) are reported in Table 2.
Table 4. Multivariate analysis (Cox proportional hazard models for
either OS or PFS)
Parameter HR 95% CI P
Multivariate analysis of OS
(103 subjects, 6 deaths)
MTV (increments of 102 ml) 0.96 0.66-1.40 .833
TLG (increments of 103) 1.49 1.18-1.89 .001
Multivariate analysis of PFS
(103 subjects, 13 events)
Bulky disease (,10 cm vs $10 cm) 1.73 0.31-9.52 .526
MTV (increments of 102 mL) 1.03 0.80-1.33 .812
TLG (increments of 103 mL) 1.36 1.16-1.58 ,.001
Each as a whole was statistically significant, and in both models, TLG resulted in
a significantly longer survival time after controlling for mediastinal bulk and MTV in
PFS and for MTV in OS.
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improving their poor prognosis. In this setting, TLGmay be a tool to
select patients to be considered for elective front-line consolidation
with myeloablative therapies. An alternative strategy for this group
might be to use the dose-adjusted etoposide, prednisone, vincristine,
cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R)
regimen, which has demonstrated very promising results7 but
may not be necessary for the large proportion of patients who are
probably curable with R-CHOP or R-MACOP-B/R-VACOP-B
alone.8 Even if PET restaging at the end of chemotherapy can be used
to reassess the risk of progression,8 a reliable baseline prognostic
marker might allow us to determine who needs more complex
infusional therapy and who is just as likely to be cured with the
conventional regimens.
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